181 related articles for article (PubMed ID: 31244179)
1. Fluorescence Detection of Prostate Cancer by an Activatable Fluorescence Probe for PSMA Carboxypeptidase Activity.
Kawatani M; Yamamoto K; Yamada D; Kamiya M; Miyakawa J; Miyama Y; Kojima R; Morikawa T; Kume H; Urano Y
J Am Chem Soc; 2019 Jul; 141(26):10409-10416. PubMed ID: 31244179
[TBL] [Abstract][Full Text] [Related]
2. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.
Mazzocco C; Fracasso G; Germain-Genevois C; Dugot-Senant N; Figini M; Colombatti M; Grenier N; Couillaud F
Sci Rep; 2016 Mar; 6():23314. PubMed ID: 26996325
[TBL] [Abstract][Full Text] [Related]
3. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
4. PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.
Derks YHW; Löwik DWPM; Sedelaar JPM; Gotthardt M; Boerman OC; Rijpkema M; Lütje S; Heskamp S
Theranostics; 2019; 9(23):6824-6839. PubMed ID: 31660071
[TBL] [Abstract][Full Text] [Related]
5. PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Bao K; Lee JH; Kang H; Park GK; El Fakhri G; Choi HS
Chem Commun (Camb); 2017 Feb; 53(10):1611-1614. PubMed ID: 28085163
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
7. A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging.
Zhang J; Rakhimbekova A; Duan X; Yin Q; Foss CA; Fan Y; Xu Y; Li X; Cai X; Kutil Z; Wang P; Yang Z; Zhang N; Pomper MG; Wang Y; Bařinka C; Yang X
Nat Commun; 2021 Sep; 12(1):5460. PubMed ID: 34526506
[TBL] [Abstract][Full Text] [Related]
8. Application of an inhibitor-based probe to reveal the distribution of membrane PSMA in dSTORM imaging.
Jing Y; Cai M; Zhou L; Jiang J; Gao J; Wang H
Chem Commun (Camb); 2020 Nov; 56(86):13241-13244. PubMed ID: 33030161
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
10. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
[TBL] [Abstract][Full Text] [Related]
13. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
15. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
16. A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer.
Zhou H; Liu Y; Zhang X; Chen K; Li Y; Xu X; Xu B
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566085
[No Abstract] [Full Text] [Related]
17. A Fluorescent, [
Guo H; Kommidi H; Vedvyas Y; McCloskey JE; Zhang W; Chen N; Nurili F; Wu AP; Sayman HB; Akin O; Rodriguez EA; Aras O; Jin MM; Ting R
ACS Chem Biol; 2019 Jul; 14(7):1449-1459. PubMed ID: 31120734
[TBL] [Abstract][Full Text] [Related]
18. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer.
Kularatne SA; Thomas M; Myers CH; Gagare P; Kanduluru AK; Crian CJ; Cichocki BN
Clin Cancer Res; 2019 Jan; 25(1):177-187. PubMed ID: 30201762
[TBL] [Abstract][Full Text] [Related]
20. A cell-impermeable luminogenic probe for near-infrared imaging of prostate-specific membrane antigen in prostate cancer microenvironments.
Yang X; Nao SC; Lin C; Kong L; Wang J; Ko CN; Liu J; Ma DL; Leung CH; Wang W
Eur J Med Chem; 2023 Nov; 259():115659. PubMed ID: 37499288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
